Indication
For the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.
Medicine details
- Medicine name:
- melatonin (Slenyto)
- SMC ID:
- SMC2306
- Pharmaceutical company
- Flynn Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Publication due date:
- 11 January 2021
- SMC meeting date:
- 01 December 2020
- Patient group submission deadline:
- 02 November 2020